S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
NASDAQ:ALLO

Allogene Therapeutics (ALLO) Stock Price, News & Analysis

$3.47
+0.01 (+0.29%)
(As of 04/19/2024 ET)
Today's Range
$3.38
$3.56
50-Day Range
$3.46
$5.63
52-Week Range
$2.23
$6.89
Volume
2.01 million shs
Average Volume
2.58 million shs
Market Capitalization
$586.74 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.94

Allogene Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.71 Rating Score
Upside/​Downside
272.8% Upside
$12.94 Price Target
Short Interest
Bearish
29.33% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.04mentions of Allogene Therapeutics in the last 14 days
Based on 3 Articles This Week
Insider Trading
Acquiring Shares
$684 Bought Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.93 out of 5 stars

Medical Sector

589th out of 911 stocks

Biological Products, Except Diagnostic Industry

96th out of 150 stocks

ALLO stock logo

About Allogene Therapeutics Stock (NASDAQ:ALLO)

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

ALLO Stock Price History

ALLO Stock News Headlines

Allogene Therapeutics, Inc. (NASDAQ:ALLO) Short Interest Update
SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
3 Meme Stocks to Sell and Replace With Meme Coins
SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
ALGS Apr 2024 2.500 call
See More Headlines
Receive ALLO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Allogene Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/14/2024
Today
4/19/2024
Next Earnings (Estimated)
5/01/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:ALLO
Fax
N/A
Employees
232
Year Founded
2018

Price Target and Rating

Average Stock Price Target
$12.94
High Stock Price Target
$28.00
Low Stock Price Target
$7.00
Potential Upside/Downside
+269.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.71
Research Coverage
7 Analysts

Profitability

Net Income
$-327,270,000.00
Net Margins
-202,366.25%
Pretax Margin
-344,489.50%

Debt

Sales & Book Value

Annual Sales
$90,000.00
Book Value
$3.04 per share

Miscellaneous

Free Float
122,761,000
Market Cap
$591.82 million
Optionable
Optionable
Beta
0.81

Social Links

7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

  • Dr. Arie S. Belldegrun F.A.C.S. (Age 75)
    M.D., Co-Founder & Executive Chairman
    Comp: $714.25k
  • Dr. David D. Chang M.D. (Age 64)
    Ph.D., Co-Founder, President, CEO & Director
    Comp: $1.1M
  • Mr. Joshua A. Kazam (Age 47)
    Co-Founder & Director
    Comp: $711k
  • Mr. Timothy L. Moore Ph.D. (Age 63)
    Executive VP & Chief Technical Officer
  • Mr. Earl M. Douglas Esq. (Age 61)
    General Counsel & Compliance Officer
  • Ms. Susan R. Lundeen (Age 58)
    Chief People Officer
  • Ms. Christine Cassiano
    Executive VP, Chief Corporate Affairs & Brand Strategy Officer
  • Dr. Zachary J. Roberts M.D. (Age 46)
    Ph.D., Executive VP of Research & Development and Chief Medical Officer
  • Yinlin Chen
    Senior Vice President of Finance
  • Mr. David M. Tanen J.D. (Age 53)
    Secretary

ALLO Stock Analysis - Frequently Asked Questions

Should I buy or sell Allogene Therapeutics stock right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allogene Therapeutics in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ALLO shares.
View ALLO analyst ratings
or view top-rated stocks.

What is Allogene Therapeutics' stock price target for 2024?

7 analysts have issued 1-year price targets for Allogene Therapeutics' stock. Their ALLO share price targets range from $7.00 to $28.00. On average, they anticipate the company's stock price to reach $12.94 in the next twelve months. This suggests a possible upside of 272.8% from the stock's current price.
View analysts price targets for ALLO
or view top-rated stocks among Wall Street analysts.

How have ALLO shares performed in 2024?

Allogene Therapeutics' stock was trading at $3.21 at the beginning of the year. Since then, ALLO stock has increased by 8.1% and is now trading at $3.47.
View the best growth stocks for 2024 here
.

Are investors shorting Allogene Therapeutics?

Allogene Therapeutics saw a increase in short interest in March. As of March 31st, there was short interest totaling 30,620,000 shares, an increase of 10.3% from the March 15th total of 27,750,000 shares. Based on an average daily trading volume, of 2,610,000 shares, the days-to-cover ratio is presently 11.7 days. Approximately 29.3% of the shares of the stock are sold short.
View Allogene Therapeutics' Short Interest
.

When is Allogene Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our ALLO earnings forecast
.

How were Allogene Therapeutics' earnings last quarter?

Allogene Therapeutics, Inc. (NASDAQ:ALLO) released its earnings results on Thursday, March, 14th. The company reported ($0.43) EPS for the quarter, beating analysts' consensus estimates of ($0.47) by $0.04. The company earned $0.02 million during the quarter, compared to analysts' expectations of $0.05 million. Allogene Therapeutics had a negative net margin of 202,366.25% and a negative trailing twelve-month return on equity of 53.76%.

What is David Chang's approval rating as Allogene Therapeutics' CEO?

2 employees have rated Allogene Therapeutics Chief Executive Officer David Chang on Glassdoor.com. David Chang has an approval rating of 100% among the company's employees. This puts David Chang in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Allogene Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Allogene Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Pfizer (PFE), Teladoc Health (TDOC), AbbVie (ABBV), Alibaba Group (BABA), Bristol-Myers Squibb (BMY) and CRISPR Therapeutics (CRSP).

When did Allogene Therapeutics IPO?

Allogene Therapeutics (ALLO) raised $272 million in an initial public offering (IPO) on Thursday, October 11th 2018. The company issued 16,000,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, J.P. Morgan, Cowen and Jefferies acted as the underwriters for the IPO.

Who are Allogene Therapeutics' major shareholders?

Allogene Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Los Angeles Capital Management LLC (0.09%) and Bourgeon Capital Management LLC (0.03%). Insiders that own company stock include Alison Moore, Arie Belldegrun, David D Chang, Deborah M Messemer, Eric Thomas Schmidt, Geoffrey M Parker, Owen N Witte, Owen N Witte, Rafael Amado, Stephen Mayo and Veer Bhavnagri.
View institutional ownership trends
.

How do I buy shares of Allogene Therapeutics?

Shares of ALLO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ALLO) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners